Part B Reference Pricing Faces 'Clinical' As Well As 'Political' Obstacles
Executive Summary
Medicare pilot program on value-based purchasing could be challenged by a lack of therapeutic consensus as much as by opposition towards reduced reimbursement.
You may also be interested in...
US Sen. Cassidy On Drug Costs: Exclusivity Based on Innovation, Reference Pricing Proposed
White paper released by Sen. Cassidy, R-La., and upcoming hearing at Senate Health, Education, Labor and Pensions Committee are aimed at building consensus around legislation to lower prices.
A Look At Payers' Early Game Plans For Driving Biosimilar Use
Interviews with US payers suggest that at first they are more likely to focus on promoting biosimilars in treatment-naïve patients, as opposed to switching those on branded drugs, according to a new Datamonitor report.
A Look At Payers' Early Game Plans For Driving Biosimilar Use
Interviews with US payers suggest that at first they are more likely to focus on promoting biosimilars in treatment-naïve patients, as opposed to switching those on branded drugs, according to a new Datamonitor report.